泰和诚医疗上涨2.5%，报6.16美元/股，总市值2674.50万美元

Financial Performance - As of June 30, 2024, the total revenue of Taihe Cheng Medical (CCM) is 219 million RMB, representing a year-on-year decrease of 23.09% [1] - The net profit attributable to the parent company is -172 million RMB, showing a significant year-on-year decline of 89.33% [1] Company Overview - Taihe Cheng Medical Group Limited, listed on the New York Stock Exchange in 2009, is primarily engaged in medical services, focusing on cancer prevention, diagnosis, education, and research [2] - The company provides third-party tumor imaging diagnosis and radiation therapy services, operates specialized cancer hospitals, outpatient departments, independent imaging centers, and proton centers [2] - In 2015, Taihe Cheng signed a long-term strategic cooperation agreement with the University of Texas MD Anderson Cancer Center to enhance cancer treatment and research capabilities in China and Singapore [2]